Discover our portfolio
Co-founded by Truffle, Symetis has developed new implant systems for transaortic valves.
The ACURATE valves are designed to treat patients suffering from severe and symptomatic aortic valve stenosis, who are considered at high risk for surgical valve replacement.
Instead of open-heart surgery, the replacement valve is delivered via a transcatheter percutaneous delivery system.
The ACURATE platform is recognized for its ease of use during valve implantation.
The company was sold in May 2017 to Boston Scientific for a total amount of $ 435M.
Contact Truffle Capital
5 Rue de la Baume, 75008 Paris, France
Tel: +33 1 82 28 46 00